Log in

MeiraGTx Stock Price, News & Analysis (NASDAQ:MGTX)

$13.91
-0.28 (-1.97 %)
(As of 10/16/2019 06:00 AM ET)
Today's Range
$13.80
Now: $13.91
$14.46
50-Day Range
$14.17
MA: $17.84
$21.34
52-Week Range
$8.53
Now: $13.91
$30.23
Volume378,441 shs
Average Volume168,458 shs
Market Capitalization$464.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
CUSIPN/A
CIKN/A
Phone646-490-2965

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.96 per share

Profitability

Net Income$-82,870,000.00

Miscellaneous

Employees68
Market Cap$464.16 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.


MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings PLC (NASDAQ:MGTX) released its earnings results on Wednesday, August, 7th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.47. The firm earned $1.98 million during the quarter. View MeiraGTx's Earnings History.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for MeiraGTx.

What price target have analysts set for MGTX?

3 analysts have issued twelve-month target prices for MeiraGTx's stock. Their forecasts range from $30.00 to $45.00. On average, they expect MeiraGTx's stock price to reach $38.33 in the next twelve months. This suggests a possible upside of 175.6% from the stock's current price. View Analyst Price Targets for MeiraGTx.

What is the consensus analysts' recommendation for MeiraGTx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.

What are Wall Street analysts saying about MeiraGTx stock?

Here are some recent quotes from research analysts about MeiraGTx stock:
  • 1. Chardan Capital analysts commented, "We rate MeiraGTx Buy on the forward- looking approach Meira management has taken to develop one of the broadest pipelines in all of AAV-based GT, including one with both lower-risk IRD opportunities for early wins and with higher-risk large-market opportunities that could generate profound investment returns." (9/23/2019)
  • 2. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (5/29/2019)

Has MeiraGTx been receiving favorable news coverage?

Press coverage about MGTX stock has been trending very negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MeiraGTx earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for MeiraGTx.

Are investors shorting MeiraGTx?

MeiraGTx saw a increase in short interest in September. As of September 30th, there was short interest totalling 765,900 shares, an increase of 22.7% from the August 30th total of 624,200 shares. Based on an average trading volume of 185,700 shares, the days-to-cover ratio is presently 4.1 days. Currently, 3.6% of the company's shares are sold short. View MeiraGTx's Current Options Chain.

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include Fate Therapeutics (FATE), Intercept Pharmaceuticals (ICPT), Uniqure (QURE), AbbVie (ABBV), Kadmon (KDMN), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Global Blood Therapeutics (GBT) and Galmed Pharmaceuticals (GLMD).

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the folowing people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
  • Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
  • Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
  • Mr. Micah Zajic, VP of Corp. Devel.

When did MeiraGTx IPO?

(MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bowling Portfolio Management LLC (0.04%). View Institutional Ownership Trends for MeiraGTx.

Which institutional investors are buying MeiraGTx stock?

MGTX stock was acquired by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC. View Insider Buying and Selling for MeiraGTx.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $13.91.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $464.16 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.

What is MeiraGTx's official website?

The official website for MeiraGTx is http://www.meiragtx.com/.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]


MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel